Hydroflumethiazide

CHEMBL1763 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
331.3 g/mol
LogP
0.4
Phase
4

A thiazide diuretic used to treat high blood pressure and edema by increasing urinary sodium and water excretion from the kidneys, reducing blood volume and relaxing blood vessel walls. It may be used alone or in combination with other antihypertensive agents for better blood pressure control. Monitoring of electrolytes, particularly potassium, is recommended during treatment.

分子量

331.3000 g/mol

LogP

0.40

TPSA

135.00 Ų

リピンスキーの五則

適合

治療領域

作用機序

Provides essential ions for maintaining fluid balance, nerve conduction, muscle contraction, and acid-base homeostasis. Supplementation corrects electrolyte imbalances.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Provides essential ions for maintaining fluid balance, nerve conduction, muscle contraction, and acid-base homeostasis. Supplementation corrects electrolyte imbalances.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NCNS2(=O)=O

InChI

InChI=1S/C8H8F3N3O4S2/c9-8(10,11)4-1-5-7(2-6(4)19(12,15)16)20(17,18)14-3-13-5/h1-2,13-14H,3H2,(H2,12,15,16)

Molecular Formula

C8H8F3N3O4S2

HBD / HBA

3 / 10

回転可能結合数

1

重原子数

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A thiazide diuretic used to treat high blood pressure and edema by increasing urinary sodium and water excretion from the kidneys, reducing blood volume and relaxing blood vessel walls. It may be used alone or in combination with other antihypertensive agents for better blood pressure control. Monitoring of electrolytes, particularly potassium, is recommended during treatment.

Provides essential ions for maintaining fluid balance, nerve conduction, muscle contraction, and acid-base homeostasis. Supplementation corrects electrolyte imbalances.

Yes, Hydroflumethiazide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1763. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3647. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.